Literature DB >> 17311333

Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time.

Tatjana Tallo1, Helene Norder, Valentina Tefanova, Tõnu Krispin, Jelena Schmidt, Madis Ilmoja, Karen Orgulas, Kaije Pruunsild, Ludmilla Priimägi, Lars O Magnius.   

Abstract

During the last decade, there has been a dramatic increase in intravenous drug use in young adults in Estonia with an increased incidence of both hepatitis B and C as a consequence. Since genetic data are limited regarding hepatitis C virus (HCV) strains in Estonia, the aim of the study was to characterize HCV strains in different risk groups to determine their relatedness to strains from other geographical regions. Three hundred fifty-three anti-HCV positive sera collected during 1994-2004 from hospitalized patients, blood donors and health care workers were used as source of HCV RNA. Two hundred nine (59%) of the sera were positive for HCV RNA by PCR directed to the 5'-UTR region. For 174 strains the HCV subtype was determined by analyses of the NS5B and/or the 5'UTR-core regions. 1b (71%) was the most common subtype followed by 3a (24%), 2c (2%), 1a (1%), and 2a (1%). The 1b and 3a strains were similar to strains from other regions of the former USSR. Within genotype 1b there were several HCV lineages. However, for 3a there seemed to be two separate introductions into Estonia. There was a relative shift from subtype 1b to 3a in 1999-2000 with a further replacement of 3a with 1b in intravenous drug users in 2001 and onwards (P < 0.05). However, both subtypes were found to co-circulate in the community independent of risk factors. One patient was infected with the 2k/1b recombinant presumed to originate from St. Petersburg being the first isolate of this recombinant recovered outside Russia. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311333     DOI: 10.1002/jmv.20828

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  25 in total

Review 1.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

Review 2.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.

Authors:  Marine Karchava; Jesper Waldenström; Monica Parker; Renee Hallack; Lali Sharvadze; Lana Gatserelia; Nikoloz Chkhartishvili; Natia Dvali; Lela Dzigua; Ekaterine Dolmazashvili; Helene Norder; Tengiz Tsertsvadze
Journal:  Hepatol Res       Date:  2015-03-24       Impact factor: 4.288

Review 4.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Naturally occurring genotype 2b/1a hepatitis C virus in the United States.

Authors:  Dipankar Bhattacharya; Molly A Accola; Israr H Ansari; Rob Striker; William M Rehrauer
Journal:  Virol J       Date:  2011-10-03       Impact factor: 4.099

6.  HEPATITIS C VIRUS GENOTYPES IN INJECTING DRUG USERS FROM ROMANIA.

Authors:  Camelia Sultana; Codruta Vagu; Aura Temereanca; Camelia Grancea; Josefina Slobozeanu; Simona Ruta
Journal:  Cent Eur J Med       Date:  2011-10

7.  Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection.

Authors:  Elijah Paintsil; Sergei V Verevochkin; Elena Dukhovlinova; Linda Niccolai; Russell Barbour; Edward White; Olga V Toussova; Louis Alexander; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2009-08-27       Impact factor: 6.526

Review 8.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

9.  Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.

Authors:  Vasily Isakov; Natalia Gankina; Viacheslav Morozov; Kathryn Kersey; Sophia Lu; Anu Osinusi; Evguenia Svarovskaia; Diana M Brainard; Riina Salupere; Elena Orlova-Morozova; Konstantin Zhdanov
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

10.  Anti-HCV prevalence in the general population of Lithuania.

Authors:  Valentina Liakina; Jonas Valantinas
Journal:  Med Sci Monit       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.